

Research institute partnerships 2015

Brady Huggett

With 11 deals, the US National Institutes of Health once again tops our list of industry partnering in 2015. Second on the list is Memorial Sloan Kettering, with five

deals, the same number as 2014. Outside the United States, 2015 was a quiet year for the UK's Medical Research Council, which sealed just two deals (down from 11 in 2014; Fig. 1);

the Paoli-Calmettes Institute in France and the Shanghai Cancer Institute in China entered the list for the first time. As always, oncology deals continue to dominate the landscape.

Table 1 Research institute partnerships 2015

Institute	Partners	Details
National Institutes of Health (11 deals)	National Cancer Institute (NCI), SeraCare	Cooperative Research and Development Agreement (CRADA) to create reference materials and positive controls for cancer assays.
	NCI, Foundation Medicine	Study on unique molecular indicators of tumors associated with exceptional drug responses.
	NCI, Kite Pharma	Partners amend deal to include research on the immune response to tumor neoantigens.
	NCI, Lion Biotechnologies	CRADA amended to include four new indications for tumor-infiltrating lymphocyte therapy.
	National Center for Advancing Translational Sciences, Firststring	CRADA to develop a connexin-based peptide therapeutic, ACT1, as a topical ophthalmic therapy for diabetic keratopathy and persistent corneal defects.
	National Institutes of Health (NIH), GlaxoSmithKline	Partnership to develop one or more broadly neutralizing monoclonal antibodies against HIV infection.
	NIH, Wyeth Nutrition	Five-year partnership called the 'Baby Connectome Project' studying brains of healthy children up to 5 years old.
	NIH, GenVec	Collaboration using GenVec's gorilla adenovirus vectors of low human seroprevalence to deliver antigens for a variety of malaria vaccine candidates.
	NIH, others	Partners in an 'Alzheimer's Big Data' portal for use by the research community.
Memorial Sloan Kettering (5 deals)	NIH, University of Massachusetts Medical School and Scripps, Padlock	Collaboration to determine the role of individual peptidylarginine deiminase (PAD) enzymes in certain animal disease models and to evaluate PAD inhibitors in enzymatic assays, animal models and human cellular systems.
	NIH/National Institute of Alcohol Abuse and Alcoholism, Adnex	Collaboration to evaluate the pharmacology of ADX71441, a γ -aminobutyric acid B receptor-positive allosteric modulator, in preclinical models of alcohol use disorder.
	Adimab	Collaboration with MD Anderson and Memorial Sloan Kettering on antibody discovery.
	Genoece Biosciences	Collaboration to screen T-cell responses of melanoma and non-small-cell lung cancer patients treated with checkpoint inhibitors against patient-specific putative neoantigens.
	Cesca Therapeutics	Partnership to use Cesca's CellWerks portfolio of devices for intralaboratory stem cell purification applications.
Multiple Myeloma Research Foundation (3 deals)	Illumina	Collaboration on noninvasive cancer diagnosis and monitoring.
	Peregrine Pharmaceuticals	Collaboration on combinations of phosphatidyl serine-targeting agents, including bavixumab, with other immune modulators.
	Inflection Biosciences	Preclinical testing of Inflection's dual-mechanism phosphatidyl inositol mannoside/phosphatidyl inositol 3-kinase inhibitor, IBL-202.
Cold Spring Harbor (2 deals)	GNS Healthcare	Initiative to deploy predictive big data analytics on patient data from CoMMpass Study in multiple myeloma.
	Adaptive, Onyx	Collaboration to perform sequencing-based assessment of minimal residual disease on multiple myeloma patients over 5 years.
Cleveland Clinic (2 deals)	Hairpin Technologies	Initiative to expand the commercial distribution and research use of short hairpin RNA technology.
	GlaxoSmithKline	Collaboration with GSK on obesity and type 2 diabetes.
Paoli-Calmettes Institute (2 deals)	Human Longevity	Collaboration to apply whole-genome, cancer and microbiome sequencing to heart disease.
	Procter & Gamble	Cleveland HeartLab to collaborate on a diagnostic and management solution for a heart disease biomarker discovered by the Cleveland Clinic.
The Technion Institute	Innate Pharma	Initiative to conduct translational research aimed at hematological cancers and at identifying associated biomarkers.
	Eisai	Collaboration to study protein-protein inhibitors for oncology indications.

Source: BioCentury




Figure 1 Most active research institutes, 2015. Source: BioCentury.

First Rounders Podcast: Tom Maniatis

Tom Maniatis is a founder of Kallyope, and head of the Maniatis lab at Columbia University. Among other things, he's founded several biotech and authored a manual nicknamed "the bible of cloning." His conversation with *Nature Biotechnology* covers being the first in his family to go to college, the moratorium on recombinant DNA research in Cambridge, Massachusetts, and his long relationship with Jim Watson at Cold Spring Harbor. <http://www.nature.com/nbt/podcast/index.html>



Brady Huggett is Business Editor at Nature Biotechnology.